SCHEMBL15076182

SCHEMBL15076182

Cc1nc2c3c(nn2cc1Cl)CNC3

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16286567 0.98 CYP1A2 (0.30) CYP1A2
Hydrochloric Acid SCHEMBL16295652 0.86
SCHEMBL15061959 0.84 PTGS2 (0.32) CYP1A2
Hydrochloric Acid SCHEMBL22828961 0.78
SCHEMBL15062026 0.72 PTGS2 (0.32) CYP1A2
SCHEMBL8210241 0.72 DPP4 (0.38) CYP1A2
SCHEMBL15061962 0.72 ATR (0.34)
Hydrochloric Acid SCHEMBL15048789 0.71 ATR (0.34)
Hydrochloric Acid SCHEMBL15048944 0.71 PTGS2 (0.32) CYP1A2
SCHEMBL15061966 0.71 HTR6 (0.34) CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3008068-B1 TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES ASCENEURON SA (CH) 2020-12-30 EP disclosed
US-9505769-B2 Tetraaza-cyclopenta[a]indenyl derivatives ASCENEURON SA (CH) 2016-11-29 US disclosed
US-9505769-B2 Tetraaza-cyclopenta[a]indenyl derivatives ASCENEURON SA (CH) 2016-11-29 US disclosed
EP-2794608-B1 TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS MERCK PATENT GMBH (DE) 2016-09-14 EP disclosed
US-9403835-B2 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators ARES TRADING S.A. (CH) 2016-08-02 US disclosed
US-9403835-B2 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators ARES TRADING S.A. (CH) 2016-08-02 US disclosed
US-9403835-B2 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators ARES TRADING S.A. (CH) 2016-08-02 US disclosed
US-20160137648-A1 TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES ASCENEURON SA (CH) 2016-05-19 US disclosed
US-20160137648-A1 TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES ASCENEURON SA (CH) 2016-05-19 US disclosed
WO-2014198808-A1 TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES ASCENEURON SA (CH) 2014-12-18 WO disclosed
EP-2813505-A1 Tetraaza-cyclopenta[a]indenyl derivatives Asceneuron SA (CH) 2014-12-17 EP disclosed
WO-2013091773-A1 TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS MERCK PATENT GMBH (DE) 2013-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160137648-A1 TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES CHRM1, CHRM2, CHRM3 CYP1A2 640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.